Novo Nordisk's sales increased by 23% in Danish kroner and by 24% at constant exchange rates to DKK 204.7 billion in the first nine months of 2024

Financial Performance - Operating profit increased by 21% in Danish kroner and by 22% at constant exchange rates (CER) to DKK 91.6 billion [1] - Net sales grew by 23% in Danish kroner (24% at CER) to DKK 204,720 million [2] - Net profit increased by 18% to DKK 72,758 million [2] - Diluted earnings per share grew by 19% to DKK 16.29 [2] Regional Sales Performance - North America Operations sales increased by 31% in Danish kroner (31% at CER) [1] - International Operations sales grew by 13% in Danish kroner (15% at CER) [1] Therapeutic Area Performance - Diabetes and Obesity care sales increased by 25% in Danish kroner (26% at CER) to DKK 191.8 billion [1] - GLP-1 diabetes sales grew by 25% in Danish kroner (26% at CER) [1] - Obesity care sales surged by 44% in Danish kroner (44% at CER) to DKK 43.7 billion [1] - Rare disease sales increased by 3% in both Danish kroner and at CER [1] R&D Progress - Completed phase 2a trial with monlunabant in obesity, with phase 2b trial planned for 2025 [1] - Oral semaglutide demonstrated statistically significant reduction in major adverse cardiovascular events in the SOUL trial [1] - Semaglutide 2.4 mg showed superior improvement in liver fibrosis and MASH resolution in the ESSENCE trial [1] 2024 Outlook - Sales growth expected to be 23-27% at CER [1] - Operating profit growth projected at 21-27% at CER [1] - Growth in Danish kroner expected to be 1 percentage point lower than CER for sales and 2 percentage points lower for operating profit [1] Company Overview - Global healthcare company founded in 1923, headquartered in Denmark [4] - Focuses on defeating serious chronic diseases, with heritage in diabetes [4] - Employs approximately 72,000 people in 80 countries [4] - Markets products in around 170 countries [4] - Listed on Nasdaq Copenhagen (Novo-B) and New York Stock Exchange (NVO) [4] Leadership Commentary - CEO highlighted strong performance driven by GLP-1-based diabetes and obesity treatments [3] - Emphasized positive R&D read-outs across semaglutide portfolio [3]